HANGZHOU, China, 22 November 2024 -- E-nitiateBio (Hangzhou) Co., Ltd. (‘E-nitiateBio’) has entered into a significant licensing collaboration with Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare”). E-nitiateBio has licensed the development and commercialization rights for QY101 inhaler in China to Health Yuan, while E-nitiateBio will keep the rights for the external preparation, and the two parties will work together to promote the development and marketing of this innovative drug.
QY101 is an innovative PDE4 inhibitor with the potential to treat self-immune diseases such as plaque psoriasis and atopic dermatitis. Previously, QY101 ointment has completed Phase II clinical studies in China and showed significant efficacy and safety. The collaboration builds on the findings of QY101 to further develop inhalation dosage forms to meet the needs of different patient groups.
About E-nitiateBio :
Founded in 2020, E-nitiateBio (Hangzhou) Co., Ltd. is an innovative pharmaceutical company that focuses on innovative drugs for autoimmune diseases, develops breakthrough drugs through independent research and development and strategic cooperation, and is committed to addressing the unmet needs of patients and improving the quality of human life.
The company is headquartered in Hangzhou, Zhejiang, and has set up a clinical center and a R&D center in Shanghai. E-nitiateBio is a key introduction project of the Linping National Economic and Technological Zone in Hangzhou. It won the first prize in the "2020 Hangzhou Overseas High-Level Talent Innovation and Entrepreneurship Competition (Life and Health Group)" and received about 0.1 billion ren-min yuan of angel investment from healthcare focused industrial capital Betapharm. E-nitiateBio also established a strategic partnership with Betapharm to jointly promote the clinical development of its drug candidates. In 2022, the company completed Series A financing of nearly 100 million CNY.
Upholding the values of "embracing competition, relentless pursuit, and candid dedication", E-nitiateBio has assembled a team of scientists with successful new drug whole-phase development experience from early new drug research and development to clinical translation, and clinical management. The company owns global patents for several innovative Class 1 drug candidates including QY201, QY101 and QY211, with multiple indications rapidly advancing into different clinical stages, and several IND filings are on the horizon. The company pays attention to the unmet clinical needs, independently develops differentiated molecules, and has a prospective portfolio in autoimmune diseases. Through tireless efforts, E-nitiateBio strives to become a leader in the development of innovative drugs for autoimmune diseases.
About Joincare:
Joincare founded in 1992, Healthy Meta (600380.SH) is an innovative, research-based integrated pharmaceutical group. It owns two large listed companies, namely, Joincare and Lizhu Pharmaceuticals, as well as more than 20 major holding subsidiaries. The company has always adhered to the strategy of technological innovation as the basis, with the strategic goal of building a dual-wheel drive of innovative drugs and high-barrier complex preparation technology platforms, and has diversified product matrix and pipeline of drugs under development in respiratory, analgesic, gastrointestinal, assisted reproduction, psychiatry, oncology and other areas with significant clinical needs. In the field of inhalation agents, we have a significant advantage, and have successfully developed and commercialized a number of respiratory disease drugs, and are the leader in the field of respiratory agents in China.
